Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
Pei-Chien Tsai,Hsing-Tao Kuo,Chao-Hung Hung,Kuo-Chih Tseng,Hsueh-Chou Lai,Cheng-Yuan Peng,Jing-Houng Wang,Jyh-Jou Chen,Pei-Lun Lee,Rong-Nan Chien,Chi-Chieh Yang,Gin-Ho Lo,Jia-Horng Kao,Chun-Jen Liu,Chen-Hua Liu,Sheng-Lei Yan,Ming-Jong Bair,Chun-Yen Lin,Wei-Wen Su,Cheng-Hsin Chu,Chih-Jen Chen,Shui-Yi Tung,Chi-Ming Tai,Chih-Wen Lin,Ching-Chu Lo,Pin-Nan Cheng,Yen-Cheng Chiu,Chia-Chi Wang,Jin-Shiung Cheng,Wei-Lun Tsai,Han-Chieh Lin,Yi-Hsiang Huang,Ming-Lun Yeh,Chung-Feng Huang,Meng-Hsuan Hsieh,Jee-Fu Huang,Chia-Yen Dai,Wan-Long Chung,Chi-Yi Chen,Ming-Lung Yu
DOI: https://doi.org/10.1016/j.jhep.2022.09.019
IF: 25.7
2023-02-01
Journal of Hepatology
Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS">Diabetes mellitus (DM) is known to increase the risk of hepatocellular carcinoma (HCC) among individuals with chronic hepatitis C (CHC). We aimed to evaluate whether metformin reduces HCC risk among individuals with DM and CHC after successful antiviral therapy.</AbstractText>METHODS: <AbstractText Label="METHODS">Individuals with CHC who achieved a sustained virological response (SVR) after interferon-based therapy were enrolled in a large-scale, multicenter cohort in Taiwan (T-COACH). Cases of HCC at least 1 year after SVR were identified through linkage to the catastrophic illness and cancer registry databases.</AbstractText>RESULTS: <AbstractText Label="RESULTS">Of 7,249 individuals with CHC enrolled in the study, 781 (10.8%) had diabetes and 647 (82.8%) were metformin users. During a median follow-up of 4.4 years, 227 patients developed new-onset HCC. The 5-year cumulative HCC incidence was 10.9% in non-metformin users and 2.6% in metformin users, compared to 3.0% in individuals without DM (adjusted hazard ratio [aHR] 2.83; 95% CI 1.57-5.08 and aHR 1.46; 95% CI 0.98-2.19, respectively). Cirrhosis was the most important factor significantly associated with higher HCC risk in Cox regression analysis, followed by DM non-metformin use, older age, male sex, and obesity; whereas hyperlipidemia with statin use was associated with a lower HCC risk. Using the two most crucial risk factors, cirrhosis and DM non-metformin use, we constructed a simple risk model that could predict HCC risk among individuals with CHC after SVR. Metformin use was shown to reduce the risk of all liver-related complications.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">Metformin use greatly reduced HCC risk after successful antiviral therapy in individuals with diabetes and CHC. A simple risk stratification model comprising cirrhosis and DM non-metformin use could predict long-term outcomes in individuals with CHC after SVR.</AbstractText>IMPACT AND IMPLICATIONS: <AbstractText Label="IMPACT AND IMPLICATIONS">The current study provides evidence that metformin could reduce hepatocellular carcinoma (HCC) incidence after successful antiviral therapy among those with diabetes and chronic hepatitis C in a large-scale nationwide cohort study. Although successful antiviral therapy greatly reduces HCC risk in individuals with chronic hepatitis C, those with cirrhosis, diabetes, obesity, and the elderly remain at high risk of HCC development. We demonstrated that a simple risk model composed of two crucial unfavorable factors, cirrhosis and diabetes without metformin use, predicts the risk of HCC and major liver-related complications after successful antiviral therapy in individuals with chronic hepatitis C. Metformin use is highly recommended for individuals with diabetes and chronic hepatitis C after viral eradication to reduce the risk of HCC.</AbstractText>
gastroenterology & hepatology